Predicting aromatase inhibitor-induced musculoskeletal toxicity in breast cancer
Pietro Lapidari, MD, Institut Gustave Roussy, Villejuif, France, explores the development of a predictive model for aromatase inhibitor musculoskeletal toxicity (AIMT) in postmenopausal patients with early breast cancer. Identified predictors include higher BMI, prior osteoarticular disease, baseline pain, anxiety, and the type of aromatase inhibitor used, with anastrozole showing higher AIMT risk compared to letrozole. These findings suggest actionable baseline factors and highlight the potential for early interventions to improve patient outcomes and adherence. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
